

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

p44/42 MAPK (Erk1/2) (3A7) Mouse mAb

RRID:AB_10695739

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 9107, RRID:AB_10695739

Antibody Information

URL: http://antibodyregistry.org/AB_10695739

Proper Citation: Cell Signaling Technology Cat# 9107, RRID:AB_10695739

Target Antigen: p44/42 MAPK (Erk1/2)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W. Consolidation on 10/2018: AB_10695739, AB_2235073.

Antibody Name: p44/42 MAPK (Erk1/2) (3A7) Mouse mAb

Description: This monoclonal targets p44/42 MAPK (Erk1/2)

Target Organism: monkey, rat, hamster, mink, pig, mouse, bovine, zebrafish, human

Clone ID: Clone 3A7

Antibody ID: AB_10695739

Vendor: Cell Signaling Technology

Catalog Number: 9107

Record Creation Time: 20250820T044636+0000

Record Last Update: 20250820T195403+0000

Ratings and Alerts

No rating or validation information has been found for p44/42 MAPK (Erk1/2) (3A7) Mouse mAb.

No alerts have been found for p44/42 MAPK (Erk1/2) (3A7) Mouse mAb.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 86 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Siegel F, et al. (2026) Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery, 16(1), 81.

Salomó Coll C, et al. (2025) ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis. Developmental cell.

Li B, et al. (2025) Serotonin transporter inhibits antitumor immunity through regulating the intratumoral serotonin axis. Cell, 188(14), 3823.

Almazan J, et al. (2025) Combined inhibition of focal adhesion kinase and RAF/MEK elicits synergistic inhibition of melanoma growth and reduces metastases. Cell reports. Medicine, 6(2), 101943.

Ozawa H, et al. (2025) Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5246.

Shi Y, et al. (2025) Piezo1 senses hyphae and initiates host defense against pathogenic fungi. Cell reports, 44(6), 115839.

Devos H, et al. (2025) A Naturally Occurring Urinary Collagen Type I Alpha 1-Derived Peptide Inhibits Collagen Type I-Induced Endothelial Cell Migration at Physiological Concentrations. International journal of molecular sciences, 26(15).

Decker M, et al. (2025) In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. bioRxiv : the preprint server for biology.

Frisbie L, et al. (2024) Carcinoma-associated mesenchymal stem cells promote ovarian cancer heterogeneity and metastasis through mitochondrial transfer. Cell reports, 43(8), 114551.

Bolamperti S, et al. (2024) Tgif1-deficiency impairs cytoskeletal architecture in osteoblasts by activating PAK3 signaling. eLife, 13.

Dorigi KM, et al. (2024) Accelerated drug-resistant variant discovery with an enhanced, scalable mutagenic base editor platform. Cell reports, 43(6), 114313.

Hicks HM, et al. (2024) The effects of Aurora Kinase inhibition on thyroid cancer growth and sensitivity to MAPK-directed therapies. Cancer biology & therapy, 25(1), 2332000.

Ajay AK, et al. (2024) Local vascular Klotho mediates diabetes-induced atherosclerosis via ERK1/2 and PI3-kinase-dependent signaling pathways. *Atherosclerosis*, 396, 118531.

Murata D, et al. (2024) mCAUSE: Prioritizing mitochondrial targets that alleviate pancreatic cancer cell phenotypes. *iScience*, 27(9), 110880.

Cai X, et al. (2024) Hippo-PKC β -NF κ B signaling axis: A druggable modulator of chondrocyte responses to mechanical stress. *iScience*, 27(6), 109983.

Ziegler AC, et al. (2024) S1PR3 agonism and S1P lyase inhibition rescue mice in the severe state of experimental sepsis. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 174, 116575.

Lee JK, et al. (2024) Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3 β Activation and c-Myc and Mcl-1 Proteasomal Degradation. *Cancer research communications*, 4(2), 431.

Lehman SS, et al. (2024) The *Legionella pneumophila* effector DenR hijacks the host NRas proto-oncoprotein to downregulate MAPK signaling. *Cell reports*, 43(4), 114033.

Chang Y, et al. (2024) The UBE2F-CRL5ASB11-DIRAS2 axis is an oncogene and tumor suppressor cascade in pancreatic cancer cells. *Developmental cell*, 59(10), 1317.

Postiglione AE, et al. (2023) Hydrogen peroxide-dependent oxidation of ERK2 within its D-recruitment site alters its substrate selection. *iScience*, 26(10), 107817.